Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

303.01 +5.08 (+1.71%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
50 51 Next >
US Stocks Brace For Another Day In The Red As Rally Loses Steam: Analyst Sees Market Pullback On This Indicator
The stock rally that propelled the S&P 500 and the Dow to record highs last week seems to have stalled, with Fed officials remaining non-committal about rate-cut plans. 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Earnings Scheduled For February 6, 2024
Companies Reporting Before The Bell • BP (NYSE:BP) is projected to report quarterly earnings at $1.05 per share on revenue of $53.50 billion. 
Via Benzinga
3 Fantastic Dow Stocks to Buy in February 2024
The venerable index is more representative of today's economy and these three Dow stocks to buy are brightly shining component stars. 
Via InvestorPlace
Topics Economy Stocks
Exposures Economy US Equities
NVO, LLY or AZN: Which Pharma Stock Is the Best Weight-Loss Investment?
The relaunch of Wegovy last year caused a mad dash by weight loss stocks to compete for market leadership in anti-obesity drugs. 
Via InvestorPlace
Preview: Amgen's Earnings
Via Benzinga
Is Amgen Stock a Buy Now?
The biotech has an excellent track record, but that isn't enough to make its shares attractive. 
Via The Motley Fool
Amgen Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
Expert Outlook: Amgen Through The Eyes Of 11 Analysts
Via Benzinga
Amgen Is Trying To Take On Lilly, Novo In Obesity Treatment — Here's Why Lilly Stock Just Hit A Record
Amgen is looking to rival Eli Lilly and Novo Nordisk in weight-loss drugs. 
Via Investor's Business Daily
Weight Loss Drug's New Entrant: Amgen To Compete With Novo Nordisk, Eli Lilly, As Investigational Weight Loss Drug Shows Encouraging Early Data
Amgen's AMG 133 data. Promising results in obesity drug trials, including significant weight loss and improved metabolic markers. 
Via Benzinga
IBM, Verizon, Merck stocks lead Dow to new highs
The Dow hits record highs with IBM, Verizon, Merck, and insurer Travelers leading the way; those strong stocks don't make much of a dent in S&P performance 
Via MarketBeat
Topics Stocks
Exposures US Equities
Is Amgen a Good Dividend Stock to Buy Right Now?
Its diverse product mix and strong fundamentals make a decent case. 
Via The Motley Fool
Amgen's Planning to Take a Bite Out of Cancer. Here's What It Means for the Stock.
Its new approach to treating cancer is more than just a nibble around the edges. 
Via The Motley Fool
P/E Ratio Insights for Amgen
Via Benzinga
Amgen Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
Why NASDAQ:AMGN is a Top Pick for Dividend Investors.
Balancing Dividends and Fundamentals: The Case of AMGEN INC (NASDAQ:AMGN). 
Via Chartmill
Should You Buy the Dogs of the Dow in 2024?
The popular dividend-investing strategy has been around for years. Is it right for you? 
Via The Motley Fool
Topics Stocks
Exposures US Equities
5 top healthcare stocks for earnings growth in 2024
2024 holds promise for healthcare stocks, with Humana, Elevance, and others expected to boost earnings, as analysts say many industry pressures have been removed. 
Via MarketBeat
ABBV: This Top Biotech Just Went On A Buying Spree
AbbVie stock is a buy following its recent merger & acquisition activity (Immunogen and Cerevel). 
Via Talk Markets
Stocks to Watch: 3 Companies Working on Next-Gen Weight Loss Drugs
The best weight-loss drug stocks firms improving the drugs or developing new, potentially superior weight-loss treatments. 
Via InvestorPlace
What's Going On Johnson & Johnson Stock Today?
JNJ reports strong earnings, beats expectations for Q4 of 2023, with increased sales and successful acquisitions. Stock closes lower, settles talc litigation, and delays competitor's launch. 
Via Benzinga
Topics Earnings
Exposures Financial
This 1 Bullish Move by Merck Could Drive Growth for Years to Come
It's buying a company with sophisticated biotechnology platforms that could drive lots of growth -- eventually. 
Via The Motley Fool
5 Magnificent Dividend Growth Stocks to Buy and Hold Forever
These dividend growers ought to shine in 2024 and beyond. 
Via The Motley Fool
Amgen's Blockbuster Osteoporosis Drug Prolia Flagged With FDA Strictest Warning
FDA issues serious warning on Amgen's Prolia drug, highlighting increased risk of low calcium levels in specific patient groups. 
Via Benzinga
Exposures Product Safety
Dividend Income Update December 2023
The beginning of every month is exciting for all dividend income investors as we look back at the previous month and see how much passive dividend income our portfolios generated. 
Via Talk Markets
Cathie Wood's Ark Invest Liquidates $15.8M Worth Of ProShares Bitcoin Strategy ETF Units
On Tuesday, Cathie Wood-led Ark Invest made a significant move by selling $15.84 million worth of ProShares Bitcoin Strategy ETF (NYSE:BITO) units. 
Via Benzinga
Topics ETFs
Stocks Struggle As U.S. Dollar Sees Safety Bid
Once again, we are seeing stocks struggle whenever the dollar catches a bid. But not all hope is lost for bulls, as various semiconductor stocks continue to hold up well. 
Via Talk Markets
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond
These five biotech companies could have a lot of room to run. 
Via The Motley Fool
Why Vera Therapeutics Stock Soared by 22% This Week
Executive changes and a bullish analyst take combined to boost sentiment on the company. 
Via The Motley Fool
< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
50 51 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.